The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
To examine the long-term morbidity of high dose rate brachytherapy boost (HDRBB) in prostate cancer.A phase I/II HDRBB dose escalation protocol recruited 108 men up to November 1999. Treatment combined 46Gy external beam radiation to the prostate with four fractions of HDR totalling 16 or 20Gy. Morbidity data were collected prospectively regarding urological, bowel and erectile dysfunction (ED) symptoms...